Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892099 · ClinicalTrials.gov registry record · NA
DIVINE: Dialysis Infection and Vitamin D In New England
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 105
- Enrollment target
NCT00892099: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00892099 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892099, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 105 participants
- Enrollment target
Study Summary
Infection is the second-leading cause of death in individuals requiring dialysis treatment for kidney failure. New research suggests the high risk of infection may be due in part to low levels of vitamin D, which are extremely common in kidney disease. This study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system.
Interventions
- OTHER Placebo
- DRUG Ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892099
The ClinicalTrials.gov registry entry for NCT00892099 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00892099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892099 about?
NCT00892099 is a clinical study titled "DIVINE: Dialysis Infection and Vitamin D In New England". Infection is the second-leading cause of death in individuals requiring dialysis treatment for kidney failure. New research suggests the high risk of infection may be due in part to low levels of vitamin D, which are extremely common in kidney disease. This study is designed to determine safe and ef...
What is the current status of trial NCT00892099?
This trial is currently completed. It is a NA study. The enrollment target is 105 participants. The study started on 2009-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00892099?
The interventions under investigation include: Placebo (OTHER), Ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT00892099?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.